Menarini Group
Also known as: A.Menarini Asia-Pacific Holdings Pte Ltd | A. Menarini Industrie Farmaceutiche Riunite S.r.l. | Berlin-Chemie AG Menarini Group | Berlin-Chemie Menarini | Menarini Group | Menarini International Operations Luxembourg SA | Menarini Ricerche S.p.A. - Florence-Italy
Highest phase reached
Phase 4
First clinical trial
Apr 1, 2005First marketed drug
Jan 27, 2023First NDA
Jan 27, 2023Last known activity
Jan 31, 2026
Timeline
1880s
- Jun 1, 1886
Menarini Group— Founded
1990s
- Jun 22, 1992
Berlin-Chemie AG— Acquired
2010s
- Sep 22, 2013
Silicon Biosystems— Acquired
2020s
- May 4, 2020
Stemline Therapeutics, Inc.— Acquired
- Jan 27, 2023
elacestrant— NDA Organization
- Jan 27, 2023
elacestrant— NDA Secondary Org
Drugs by trial phase (74 distinct, 67 trials)
Phase 4 (19 own, 0 via acquisition)
Phase 3 (16 own, 1 via acquisition)
Phase 2 (12 own, 8 via acquisition)
Phase 1 (7 own, 2 via acquisition)
Other trials (9 own, 0 via acquisition)
Indications
Studied for
- Acute Pain
- Arachnodactyly
- Asthma
- Atrial Fibrillation
- Breast Neoplasms
- Carcinoma, Ovarian Epithelial
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Colic
- Colorectal Neoplasms
- Communicable Diseases
- Conjunctivitis, Allergic
- Diarrhea
- Digestive System Diseases
- Dilatation, Pathologic
- Essential Hypertension
- Gastrointestinal Diseases
- Gout
- Heart Failure
- Hypertension
- Hypertrophy
- Hypoxia
- Infections
- Irritable Bowel Syndrome
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Diseases
- Lymphoma
- Lymphoma, Non-Hodgkin
- Marfan Syndrome
- Osteoarthritis
- Osteoarthritis, Knee
- Ovarian Neoplasms
- Pulmonary Disease, Chronic Obstructive
- Rhinitis
- Rhinitis, Allergic
- Surgical Wound Infection
- Syndrome
- Thrombosis
- Tumor Lysis Syndrome
- Urticaria
- Venous Thrombosis
- Ventricular Dysfunction
- Ventricular Dysfunction, Left
Marketed drugs (1)
Subsidiaries (3 direct, 3 total across the full acquisition tree)
Recent trials (50)
- NCT07242352CollaboratorPhase 3Jan 31, 2026
- NCT07222215CollaboratorPhase 2Dec 31, 2025
- NCT07159451CollaboratorPhase 2Sep 23, 2025
- NCT07156916Lead sponsorPhase 1Sep 8, 2025
- NCT07201584Lead sponsorPhase 1Sep 5, 2025
- NCT07091669Lead sponsorPhase 1Jun 16, 2025
- NCT07146711Lead sponsorPhase 1Mar 3, 2025
- NCT06534437CollaboratorPhase 2Nov 30, 2024
- NCT07036861Lead sponsorPhase 1Nov 6, 2023
- NCT05963997CollaboratorPhase 1/Phase 2Oct 9, 2023
- NCT06104423Lead sponsorPhase 4Oct 2, 2023
- NCT05810870CollaboratorPhase 2May 24, 2023
- NCT05512364CollaboratorPhase 3May 1, 2023
- NCT05513937Lead sponsorPhase 4May 12, 2022
- NCT06547242Lead sponsorPhase 1Oct 22, 2021
Details
- Founded
- Firenze, IT Jun 1, 1886
- First NDA
- Jan 27, 2023
- Last known activity
- Jan 31, 2026
Designations held
- Fast track
- Priority review